Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Oct 04, 2022 12:40pm
191 Views
Post# 35004430

RE:RE:RE:Thursday 10/13

RE:RE:RE:Thursday 10/13I would point out a company likely has some flexibility in determining the "materialness" of data from a drug trial. For example, is it material before the last patient in a trial has been observed even if they already effectively know the outcome? I actually do not know the rules around these matters but I suspect on some things, they can determine when it becomes material from an SEC perspective.

For example, in the late Spring of this year, the company told me they would have to report proof of concept if it was observed because it would be a material event. Then they changed their mind about that and determined that was not the case. So, clearly there is some flexibility, more than even they were initially aware of.

Also, drug sompanies regularly withhold material info until it can be announced at drug conferences. Like I said, I do not know the rules about this subject but it is clear to me there is flexibility in many cases. 

That being said, it is entirely possible we get "soft" data on 10/13 rather than "hard" data. We are all just guessing here. My point has been the increased activity with the brokers, the prime spots given to TH at investment conferences, the "key to the cell" type comments are all pointing in a positive direction and lead me to believe TH knows they have enough interesting data about TH-1902 to pitch a stock offering at the appropriate time and is busy getting its ducks in a row for that.

It is entirely within the realm of possibility that TH might not have as much interesting data as we would like to share on 10/13 or earlier but everyone will have their own opinion about that or any set of data a group like ours is looking at. My best guess is they have something meaningful enough to share that they have been able to get the attention of the brokers again following a long period where they could not get those brokers to give them the time of day. To me it is a pretty good "tell" about the quality of the cards they are holding on TH-1902. But it is still just an educated guess and other guesses are just a s legitimate. Moreover, given the track record here, no one cold be faulted for taking a more cautious approach to what might be in store for us next week. 

Joemare wrote: Yup. Will not be material if they wait for the 13th. They have to release the info prior. Otherwise, worthless to institutional investors. It will be perceived as more excuses and delays.....


<< Previous
Bullboard Posts
Next >>